Biblio
Circulating tumor DNA and bone marrow minimal residual disease negativity confers superior outcome for multiple myeloma patients. Haematologica. 2023.
. Circulating tumour DNA analysis predicts relapse and improves risk stratification in primary refractory multiple myeloma. Blood Cancer J. 2023;13(1):25.
Lenalidomide desensitisation for delayed cutaneous reaction: A case series and review of the literature. J Allergy Clin Immunol Pract. 2023.
.